BIOMAT Database Logo BIOMAT Database Logo

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. 2001

S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
HIV and AIDS Malignancy Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Virologic and immunologic responses were examined for 33 human immunodeficiency virus (HIV)-infected children who participated for > or = 96 weeks in a phase 1/2 protocol of 16 weeks of indinavir monotherapy, followed by the addition of zidovudine and lamivudine. At week 96, a median increase of 199 CD4+ T cells/microL and a median decrease of 0.74 log(10) HIV RNA copies/mL were observed. The relationship between control of viral replication and CD4) T cell count was examined. Patients were categorized into 3 response groups on the basis of duration and extent of control of viral replication. Of 21 children with a transient decrease in virus load of > or = 0.7 log(10) HIV RNA copies/mL from baseline, 7 experienced sustained increases in CD4+, CD4+ CD45RA+, and CD4+ CD45RO+ T cell counts. CD4+ CD45RA+ (naive) T cells were the major contributor to CD4+ T cell expansion. Continued long-term immunologic benefit may be experienced by a subset of children, despite only transient virologic suppression.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors.
October 1997, The Pediatric infectious disease journal,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
January 1995, The New England journal of medicine,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
February 2000, The Journal of infectious diseases,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors.
February 2006, The Pediatric infectious disease journal,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy.
July 1991, The Journal of pediatrics,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses.
March 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Evidence of thymic function in heavily antiretroviral-treated human immunodeficiency virus type 1-infected adults with long-term virologic treatment failure.
August 2002, The Journal of infectious diseases,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
September 2000, The Journal of infectious diseases,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
September 1997, The New England journal of medicine,
S Jankelevich, and B U Mueller, and C L Mackall, and S Smith, and S Zwerski, and L V Wood, and S L Zeichner, and L Serchuck, and S M Steinberg, and R P Nelson, and J W Sleasman, and B Y Nguyen, and P A Pizzo, and R Yarchoan
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
January 2001, Pediatrics,
Copied contents to your clipboard!